- Company
- Lucentis biosimilar of Chong Kun Dang gets domestic approval
- by Chon, Seung-Hyun Oct 24, 2022 06:08am
- Chong Kun Dang succeeded in commercializing its second biosimilar. Chong Kun Dang announced on the 20th that it has received approval from the Ministry of Food and Drug Safety for domestic items of the "Lucentis" biosimilar. The indication for "treatment of neovascular (habitual) age-related macular degeneration" has been approved. Lucenti
- Policy
- Severe AD treatments unlikely to be reimb this year
- by Lee, Tak-Sun Oct 21, 2022 05:48am
- It seems that reimbursement extensions for severe atopic dermatitis treatments like Dupxient to benefit pediatric and adolescent patients will only be possible after next year. This is because the current reimbursement review process in progress would render reimbursements within the year difficult. This news was revealed in the writte
- Policy
- Epclusa, a hepatitis C tx, costs 117,030 won
- by Kim, Jung-Ju Oct 21, 2022 05:48am
- Gilead Sciences Korea's Sofosbuvir/Velpatasvir-based chronic hepatitis C drugs Epclusa and Vosevi are expected to be listed on the 1st of next month at insurance drug prices of 117,000 won and 128,800 won, respectively. The government and insurance authorities expect to reduce health insurance finances as prices are agreed to be cheaper than alt
- Company
- Tumor-agnostic Vitrakvi lands in Big 5 tertiary hospitals
- by Eo, Yun-Ho Oct 21, 2022 05:47am
- The tumor-agnostic drug ‘Vitrakvi’ has landed in the Big 5 tertiary hospitals in Korea. According to industry sources, Bayer Korea’s neurotrophic tyrosine receptor kinase targeted anticancer drug Vitrakvi (larotrectinib) has passed the drug committees of major hospitals in Korea, including general hospitals like the Samsung Medical Ce
- Policy
- The head of the MFDS actively agrees with the opinion
- by Lee, Hye-Kyung Oct 21, 2022 05:47am
- Oh Yu-kyung, head of the Ministry of Food and Drug Safety, expressed her intention to actively agree to the introduction of active ingredients. Health and Welfare Minister Cho Kyu-hong avoided answering, saying that he would discuss various measures with the Ministry of Food and Drug Safety to ensure a smooth supply and demand of medicines in
- Company
- Celltrion develops anticancer drugs using ADC platform
- by Oct 21, 2022 05:47am
- Celltrion announced on the 17th that it has signed a contract with domestic bio company Pinotbio to introduce options for implementing ADC Linker-Payload platform technology. With this contract, Celltrion paid advance payments and secured the right to utilize Pinotbio's ADC Linker-PINOT-ADC for up to 15 targets. Celltrion plans to develop
- Policy
- Xtandi’s use expanded... reimbursement standard changed
- by Lee, Tak-Sun Oct 20, 2022 06:02am
- The scope of use for the prostate cancer treatment Xtandi soft capsule (enzalutamide, Astellas Korea) will be expanded. Although the drug was applied reimbursement only when other drugs that suppress androgen production cannot be used, reimbursement will be applied regardless of such status starting next month. On the 18th, the Health In
- Opinion
- [Reporter’s View] LG Chem’s global two-track strategy
- by Oct 20, 2022 06:02am
- LG Chem announced the acquisition of a US biotech firm on the 18th. LG Chem will invest KRW 800 billion to acquire a 100% stake in AVEO Pharmaceuticals. This is the third-largest in the history of M&As made by domestic pharmaceutical companies. It is also the largest single-company investment along with SK's acquisition of Ampac. AVEO Pharmac
- Company
- LG Chem acquires US pharma company for KRW 800 billion
- by Chon, Seung-Hyun Oct 19, 2022 05:49am
- LG Chem will invest KRW 800 billion to acquire a US bio-company. With the acquisition, the company will also be securing an anticancer drug that is being sold in the US. On the 18th, LG Chem announced that it would acquire AVEO Pharmaceuticals for $566 million (approx. KRW 800 billion). LG Chem will be acquiring a 100% stake in AVEO Pharmaceu
- Policy
- All targets for the benefit reassessment will be negotiated
- by Lee, Tak-Sun Oct 19, 2022 05:48am
- All six active ingredients-related companies that re-evaluated their benefit adequacy with the HIRA this year will meet at the negotiating table with the NHIS. In particular, the components for which the benefit maintenance has been decided will also be negotiated with the NHIS. Streptokinase and Streptodornase will negotiate the recovery
